. Author manuscript; available in PMC: 2017 Sep 25.

Published in final edited form as: Am J Gastroenterol. 2017 Jan 17;112(3):441–446. doi: 10.1038/ajg.2016.582

Table 2.

PUB Rebleeding risk by SRH up to 72 hours in Placebo Patients (N=388) – Multivariable Analysis

	Estimated Odds Ratio^*	Lower 95% CI^**	Upper 95% CI
Spurting vs. Oozing (Forrest IA, N=40 vs. IB, N=163)	6.66	2.19	20.26
Clot vs. Oozing (Forrest IIB, N=34 vs. IB, N=163)	4.11	1.27	13.25
NBVV vs. Oozing (Forrest IIA, N=151 vs. IB, N=163)	2.61	1.05	6.52

The oozing bleeding group was used as the reference and all placebo patients were included according to the baseline SRH in ulcers.

^**

CI is confidence intervals.